DashboardAll companies
Run this on your own research
Healthcare · Drug Manufacturers - General

Astellas Pharma Inc.

4503JPX¥2,512+¥25 (+0.98%)Market closed

Price Chart

Daily

Key facts

Market Cap
¥4.50T
P/E
15.4x
P/B
2.46x
ROE
17.4%

Astellas Pharma Inc.

Healthcare · Drug Manufacturers - General · FY 2026

Astellas Pharma Inc. is a prominent pharmaceutical company that engages in the research, development, manufacture, and marketing of pharmaceutical products across the globe. Headquartered in Japan, the company's core focus is on providing innovative treatments in areas such as oncology, immunology, and neuroscience, addressing significant unmet medical needs. Astellas works to enhance the health and quality of life for patients through its extensive portfolio of patented medicines and therapies. The company collaborates extensively with research institutions and other pharmaceutical entities to drive advancements in healthcare solutions. By continuously investing in cutting-edge research and technology, Astellas Pharma plays a critical role in the global healthcare industry, contributing to scientific innovation and patient care.

CEO
Mr. Naoki Okamura BSc
Employees
13,643

Company Statistics

Valuation

P/E
15.4x
P/B
2.46x
P/S
2.10x
EV/EBITDA
8.2x
P/FCF
9.5x

Margins

Gross
80.9%
EBITDA
27.2%
Operating
17.8%
Pre-Tax
17.6%
Net
13.6%

Returns

ROA
8.4%
ROE
17.4%
ROIC
11.3%

Growth (CAGR)

Rev 3Yr
12.1%
Rev 5Yr
11.4%
Op Inc 3Yr
42.4%
Net Inc 3Yr
43.5%

Financial Health

Cash & Cash Equivalents
¥281.61B
Net Debt
¥1.45T
Debt/Equity
94.8%
Interest Cov
—

Profile

Revenue
¥2.14T
Shares Out
—
Public markets · Korea, US, Japanalpha-lenz.com · Core by Treasurer
Astellas Pharma Inc. (4503) Stock Forecast 2026 ¥2,512 — Price, Financials & Analyst Targets | AlphaLenz